IBDEI1XK ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34273,0)
 ;;=N05.8^^192^1994^22
 ;;^UTILITY(U,$J,358.3,34273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34273,1,3,0)
 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Unspec
 ;;^UTILITY(U,$J,358.3,34273,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,34273,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,34274,0)
 ;;=R59.9^^192^1995^4
 ;;^UTILITY(U,$J,358.3,34274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34274,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,34274,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,34274,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,34275,0)
 ;;=R59.1^^192^1995^2
 ;;^UTILITY(U,$J,358.3,34275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34275,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,34275,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,34275,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,34276,0)
 ;;=R59.0^^192^1995^3
 ;;^UTILITY(U,$J,358.3,34276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34276,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,34276,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,34276,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,34277,0)
 ;;=Z79.01^^192^1995^5
 ;;^UTILITY(U,$J,358.3,34277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34277,1,3,0)
 ;;=3^Long Term Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,34277,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,34277,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,34278,0)
 ;;=D64.9^^192^1995^1
 ;;^UTILITY(U,$J,358.3,34278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34278,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,34278,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,34278,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,34279,0)
 ;;=R79.9^^192^1996^1
 ;;^UTILITY(U,$J,358.3,34279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34279,1,3,0)
 ;;=3^Abnormal Finding of Blood Chemistry,Unspec
 ;;^UTILITY(U,$J,358.3,34279,1,4,0)
 ;;=4^R79.9
 ;;^UTILITY(U,$J,358.3,34279,2)
 ;;=^5019594
 ;;^UTILITY(U,$J,358.3,34280,0)
 ;;=R78.71^^192^1996^2
 ;;^UTILITY(U,$J,358.3,34280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34280,1,3,0)
 ;;=3^Abnormal Lead Level in Blood
 ;;^UTILITY(U,$J,358.3,34280,1,4,0)
 ;;=4^R78.71
 ;;^UTILITY(U,$J,358.3,34280,2)
 ;;=^5019586
 ;;^UTILITY(U,$J,358.3,34281,0)
 ;;=R79.0^^192^1996^3
 ;;^UTILITY(U,$J,358.3,34281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34281,1,3,0)
 ;;=3^Abnormal Level of Blood Mineral
 ;;^UTILITY(U,$J,358.3,34281,1,4,0)
 ;;=4^R79.0
 ;;^UTILITY(U,$J,358.3,34281,2)
 ;;=^5019590
 ;;^UTILITY(U,$J,358.3,34282,0)
 ;;=R78.79^^192^1996^4
 ;;^UTILITY(U,$J,358.3,34282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34282,1,3,0)
 ;;=3^Abnormal Level of Heavy Metals in Blood
 ;;^UTILITY(U,$J,358.3,34282,1,4,0)
 ;;=4^R78.79
 ;;^UTILITY(U,$J,358.3,34282,2)
 ;;=^5019587
 ;;^UTILITY(U,$J,358.3,34283,0)
 ;;=K74.0^^192^1996^7
 ;;^UTILITY(U,$J,358.3,34283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34283,1,3,0)
 ;;=3^Hepatic Fibrosis
 ;;^UTILITY(U,$J,358.3,34283,1,4,0)
 ;;=4^K74.0
 ;;^UTILITY(U,$J,358.3,34283,2)
 ;;=^5008816
 ;;^UTILITY(U,$J,358.3,34284,0)
 ;;=E79.0^^192^1996^8
 ;;^UTILITY(U,$J,358.3,34284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34284,1,3,0)
 ;;=3^Hyperuricemia w/o Signs of Inflam Arthrit/Tophaceous Disease
 ;;^UTILITY(U,$J,358.3,34284,1,4,0)
 ;;=4^E79.0
 ;;^UTILITY(U,$J,358.3,34284,2)
 ;;=^5002978
 ;;^UTILITY(U,$J,358.3,34285,0)
 ;;=K74.69^^192^1996^5
 ;;^UTILITY(U,$J,358.3,34285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34285,1,3,0)
 ;;=3^Cirrhosis of Liver NEC
 ;;^UTILITY(U,$J,358.3,34285,1,4,0)
 ;;=4^K74.69
 ;;^UTILITY(U,$J,358.3,34285,2)
 ;;=^5008823
